CNK-UT002 / ST Phi Therap - LARVOL DELTA

Park Enterprises｜Yizun Biotechnology's first universal solid tumor cell therapy product in China has been approved for clinical trials [Google translation] (Sohu.com) - "On July 22, the new drug clinical trial application (IND) for CNK-UT002 cell injection independently developed by Yizun Biotech, a company in Qinglan Harbor China-Australia Biopharmaceutical Industry Science and Technology Park, was implicitly approved by the China National Medical Products Administration (NMPA), becoming the first universal solid tumor cell therapy approved for clinical use in China."

New trial • Oncology • Solid Tumor